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ABSTRACT
CORRELATES OF SYMPTOM DISTRESS IN 
BREAST CANCER PATIENTS RECEIVING 
CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLOUROURACIL
By
Denise J. Bakker 
The purpose of this study was to describe the 
relationship between symptom distress and health locus of 
control, perception of illness, perception of treatment 
efficacy, and social support in breast cancer patients 
receiving cyclophosphamide, methotrexate, and flourouracil 
as adjuvant chemotherapy in the outpatient setting.
A prospective descriptive correlational design was used.
A convenience sample of women (Ü = 33) with breast cancer 
was assessed using five measurement tools: the Symptom
Distress Scale (McCorkle & Young, 1978), the 
Multidimensional Health Locus of Control scale (Wallston, 
Wallston, & DeVellis, 1978), the Norbeck Social Support 
Questionnaire (Norbeck, Lindsey, & Carrieri, 1981), and two 
100-ram visual analog scales measuring perception of illness 
(Ehlke, 1988) and perception of treatment efficacy. Using 
the Pearson correlation coefficient no significant 
relationship was found between symptom distress and health 
locus of control, perception of illness, perception of 
treatment efficacy, and social support.
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CHAPTER 1 
INTRODUCTION
Oncology patients encounter many challenges throughout 
their diagnosis and treatment. Nursing's role in assisting 
the individual to maintain health and well-being requires 
that nurses identify when the individual's coping resources 
are inadequate to meet the demands imposed by treatment.
Side effects produced by chemotherapy agents administered as 
part of the disease treatment are a primary concern. The 
individual's response to treatment induced side effects can 
be identified by evaluating symptom distress.
McCorkle and Young (1978) define symptom distress as
"the degree of discomfort from the specific symptom being
experienced as perceived by the patient" (p. 374). Research
has shown that incongruencies exist in the perception of
symptom distress by care givers and the distress reported by
patients (Holmes & Eburn, 1989 and Larson, P., Viele, C.
Coleman, S., Dibble, S., & Cebulski, C ., 1993). These
incongruencies support the proposition that symptom distress
is a subjective experience whose expression is dependent on
the perception of the individual. It is important for
nurses to gain an understanding of the reported symptom
distress associated with cancer treatment in order to assist
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patients to meet the demands of symptom management. Symptom 
assessment must include identification of the factors 
influencing the perception of the symptom and the 
interpretation of the meaning to the treatment (Giardino & 
Wolf, 1993).
This study was a partial replication of work by 
GraceAnn Ehlke (1988). The purpose of this study was to 
determine the factors influencing the symptom distress 
experienced by breast cancer patients receiving 
cyclophosphamide, methotrexate, and fluorouracil (CMF) as 
adjuvant chemotherapy in the outpatient setting. Knowledge 
of these relationships will assist in identification of 
patients at risk for significant symptom distress.
CHAPTER 2 
LITERATURE AND THEORY
Conceptual Framework
Theorectical Framework
The framework used for this study is Lazarus's theory 
of psychological stress (Lazarus & Folkman, 1984). Lazarus 
defines psychological stress as "a particular relationship 
between the person and the environment that is appraised by 
the person as taxing or exceeding his or her resources and 
endangering his or her well-being" (p. 19). The concept of 
cognitive appraisal central to the theory is defined as "the 
evaluative process that determines why and to what extent a 
particular transaction or series of transactions between the 
person and the environment is stressful" (p. 19). The 
individual's appraisal of an event categorizes it as 
irrelevant, benign-positive, or stressful. "Stressful 
appraisals include harm/loss, threat, and challenge"
(p. 32). Harm/loss and threat appraisals encompass actual 
or anticipated harm or loss from the encounter. Challenge 
appraisal focuses on the potential for gain or growth from 
the encounter.
Lazarus's theory has three primary assumptions:
(a) Each individual’s perception of the situation is unique;
(b) the situation and the person's appraisal of and response 
to the situation interact in a dynamic relationship; and
(c) appraisal of the situation is influenced by "person" and 
situational factors. The "person" factors impacting 
appraisal refer to the beliefs and values held by the 
individual. The situational factors encompass the 
characteristics of the particular event.
The appraisal of an encounter influences the coping 
process. The coping process functions to manage the problem 
causing the distress and to regulate the emotional response 
to the problem. The way a person copes is influenced by the 
personal characteristics mentioned above as well as the 
person's material and social resources. (Lazarus & Folkman, 
1984).
The diagnosis and treatment of neoplastic disease set
the stage for activation of the coping process. For this
study, chemotherapy treatment is identified as the
situational factor which precipitates the coping process.
The appraisal influences the individual's management of and
emotional response to the stimulus. The individual's
perception of illness, perception of treatment efficacy,
beliefs about personal control, and perception of social
support impact the appraisal of the treatment situation.
The relationship between appraisal of the treatment
situation and the individual's coping level is dynamic.
With the implementation of coping strategies the evaluation
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of the event is modified. When coping strategies are 
ineffective or inadequate, physiological and psychological 
stress may occur. The outcome variable of symptom distress 
is one indicator of coping level.
The multidimensional nature of symptom distress 
contributes to the difficulty formulating conclusions 
regarding the factors impacting symptom distress. A review 
of the research isolates three significant variables 
impacting the experience of symptom distress;
1. Personal control: Individuals undergoing treatment 
have reported that the ability to manage side effects 
mediates the distress associated with treatment.
2. Perception of illness: Research has also indicated 
that an outlook focused on maximizing potential, despite the 
limitations imposed by treatment, has a positive effect on 
emotional well being with a subsequent decrease in reports 
of symptom distress.
3. Social support: The role of social support in
mediating symptom distress is supported by Tishelman, Taube, 
and Sachs (1991). Earlier findings by Elkhe (1988) had not 
supported this conclusion.
Figure 1. Model of conceptual framework
Symptoms
Appraisal
Social support
Symptom Distress
Personal control
Chemotherapy Treatment
Perception of illness
Perception of treatment
efficacy
The symptoms associated with the treatment event 
comprise the situational factors in the appraisal process. 
The perception of illness and treatment efficacy is the 
initial evaluation of the treatment situation as the 
individual interprets the meaning of the event in light of 
his/her life experience. The individual evaluates his/her 
ability to manage the event. The ability to exert control 
over the outcome influences the appraisal of the event as a 
challenge or threat. Finally, the social network functions 
as a resource to buffer the stress associated with the
event. This includes the individual's perception of the 
supportiveness of specific social relationships.
In this study, the outcome variable of symptom distress 
will be explored in relationship to the person factors of 
personal control, social support, and perception of illness 
and treatment efficacy given a defined treatment situation. 
Study Question
Is there a relationship between symptom distress and 
health locus of control, perception of illness, perception 
of treatment efficacy, and social support?
Hypotheses
1. Individuals with higher internal health locus of 
control scores will have lower symptom distress scores.
2. Individuals with more positive perceptions of 
illness scores will have lower symptom distress scores.
3. Individuals with more positive perceptions of 
treatment efficacy will have lower symptom distress scores.
4. Individuals with higher social support scores will 
have lower symptom distress scores.
Definition of Terms
The key concepts identified for this study are the 
following :
1. Appraisal: "The evaluative process that determines
why and to what extent a particular transaction or series of 
transactions between the person and the environment is 
stressful" (Lazarus & Folkman, 1984, p. 19). The process of
evaluation that identifies the meaning of events or 
situations.
2. Symptom Distress: "The degree of discomfort from 
the specific symptom being experienced as perceived by the 
patient" (McCorkle & Young, 1978, p. 374). The 
individual's report of discomfort from the side effects 
associated with chemotherapy.
3. Personal Control: The belief that one can shape or 
influence events and outcomes of importance.
4. Social Support: "The nature of the interactions
occurring in social relationships, especially how these are 
evaluated by the person as to their supportiveness" (Lazarus 
& Folkman, 1984, p. 249). The personal network including 
family, friends, associates, acquaintances, health care 
personnel, and spiritual counsel identified by the 
individual and the meaning of that relationship to the 
individual.
5. Perception of Illness: The evaluation of the
illness situation and its meaning.
6. Perception of Treatment Efficacy: The evaluation
of the treatment situation and its ability to provide the 
desired result.
Literature Review
Chemotherapy is an important tool in the treatments 
available for neoplastic disease. It has produced 
significant response in many cancers. However, the hope for
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response to treatment can be overshadowed by difficulties in 
coping with the treatment itself. Due to the systemic 
nature of chemotherapy treatments for malignant disease, a 
wide range of side effects affecting multiple systems can 
occur. Side effects are objective and subjective indicators 
related to illness or disease. Symptoms are side effects 
reported by the individual based on an awareness of 
sensations which depart from normal function, sensation, or 
appearance. The actual incidence of treatment related 
symptoms does not establish their significance. The 
significance of symptoms is established by the individual's 
evaluation of the physical sensation. The interpretation of 
the sensation determines the extent of discomfort associated 
with each particular symptom. Symptom occurrence is an 
essential antecedent to the perception of distress.
Research conducted describes the symptom distress 
experienced by individuals receiving chemotherapy. The 
literature reviewed investigates side effect incidence and 
the severity of distress associated with chemotherapy in 
populations with varied cancer diagnoses as well as 
populations with breast cancer diagnosis. The literature 
focuses on variables impacting symptom experience and 
mediating distress. Primary variables of interest include 
physiological variables (diagnosis, illness stage, treatment 
history, and symptom control measures), psychological 
variables (outlook, individual perception, and beliefs about
personal control), and psychosocial variables (social 
support).
Physiological and Pharmacological Variables
Nail, Jones, Greene, Schipper, and Jensen (1991) 
investigated the perceptions of side effect incidence and 
severity related to cancer diagnosis and chemotherapy 
treatment. In a heterogeneous sample (Ü = 49), a review of 
a self care diary 2 days after various courses of treatment 
revealed fatigue as the most frequent complaint followed by 
sleeping difficulty, nausea, and decreased appetite. The 
majority of side effects reported were rated as moderately 
severe. Hair loss, fatigue, and decreased appetite received 
the highest severity ratings. Self care activities, 
including obtaining extra sleep, using diversion, and taking 
anti-nausea medication, provided "some" to "moderate relief" 
from the side effects experienced.
Similar results were found by Love, Leventhal,
Easterling, and Nerenz (1989) as they investigated distress
parameters in a sample (Ü = 238) of patients with the
diagnosis of breast cancer and malignant lymphoma. Subjects
experienced a number of side effects while receiving varied
chemotherapy treatment regimens. More than 80% reported
experiencing hair loss, nausea, and tiredness at some time
throughout six cycles of chemotherapy. Forty percent
experienced vomiting, sleep disturbance, weight gain, mouth
sores, and numbness/tingling. The outcome variables
measuring distress were difficulty with chemotherapy,
10
emotional distress from chemotherapy, disruption in social 
life, and disruption in work life. Difficulty with 
chemotherapy, emotional distress, and disruption in work and 
social life from chemotherapy were experienced to some 
extent in a high percentage of the population studied, with 
higher levels of distress reported as treatment progressed. 
Nausea, vomiting, and anticipatory nausea predicted higher 
levels of the four outcome variables. Tiredness, weakness, 
and diarrhea showed a significant relationship to difficulty 
with chemotherapy. A significant positive correlation 
existed between the total number of side effects experienced 
and ratings on the outcome scales. While the side effect 
incidence and pattern were similar across drug regimens, the 
mean ratings for difficulty with treatment differed 
significantly. Cyclophosphamide, doxorubicin, and 
5-fluorouracil (CAF) regimens were consistently associated 
with the highest levels of difficulty. In looking at 
factors which enhance distress, the researchers found that 
the ability to manage or cope with side effects has an 
inverse effect on the distress measures.
In a descriptive study exploring the onset, pattern,
duration, intensity, and distress associated with fatigue in
a sample (Ü = 109) heterogeneous for diagnosis and
chemotherapy treatment, Richardson, Ream, and Wilson-Barnett
(1998) found that 89% documented fatigue at some point in
their cycle of chemotherapy. The visual analog scale and
daily diary demonstrated that the pattern of fatigue
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experienced by the study population was dependent on the 
chemotherapy regimen, timing of treatment and method of drug 
administration. The study revealed that the incidence of 
fatigue showed a comparable change in distress from fatigue 
and interference with daily activities.
Woo, Dibble, Piper, Keating, and Weiss (1998) further 
investigated the experience of fatigue in women receiving 
various cancer therapies (radiation, hormonal, chemotherapy, 
and their combinations) for breast cancer. The researchers 
found that the experience of fatigue varied by type of 
cancer therapy. Women who received combination therapy had 
the highest fatigue scores with those who received only 
radiation therapy had the lowest fatigue scores.
Tierney, Taylor, Gloss, Chetty, and Rodger (1991) 
compared pretreatment knowledge and expectations with the 
side effects experienced by women with breast cancer 
(H = 51) receiving doxorubicin for locally advanced cancer 
and cyclophosphamide for adjuvant treatment of local 
disease. Interviews revealed that the women participating 
in the study expected more difficulty with hair loss and 
sickness than other side effects associated with treatment. 
Actual experience did not corroborate those expectations. 
Tiredness, the most frequently reported side effect, was 
also identified as the most difficult. Participants 
reported a high incidence of nausea, loss of appetite, mouth 
soreness, pain, sickness, and sore eyes.
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Focusing on the experiences of women receiving 
chemotherapy for breast cancer. Green, Nail, Fieler,
Dudgeon, and Jones (1994) compared the patient-reported side 
effects and disruption in usual activities resulting from 
treatment with CMF, CAF, or cyclophosphamide, mitoxantrone, 
and fluorouracil (CNF) regimens. The sample of 86 women, 
heterogeneous for disease stage, were asked to complete a 
self-care diary recording the incidence and severity of side 
effects as well as rating the disruption which occurred in 
their usual activities on day 2 and day 5 following the 
chemotherapy treatment. The time frames were established to 
assess acute side effects rather than later effects. The 
most frequently reported side effects for all three 
regimens, independent of time, were fatigue, nausea, 
anorexia, taste changes, and headache at mild to moderate 
severity. Controlling for stage of disease, the highest 
nausea severity rating was reported by participants 
receiving CAF. Some disruption in activities of daily 
living was reported by the women in all three treatment 
groups with higher scores reported by women receiving CAF. 
Despite this, ratings for overall disruption in usual 
activity did not vary significantly with respect to 
treatment regimen.
Research conducted by Longman, Braden, and Mishel
(1996) with breast cancer patients (ü = 307) in various
stages of illness and undergoing various treatments reported
common side effects including sore arm(s), pain, difficulty
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sleeping, anxiety, nausea, swelling, depression, appetite 
change, hair loss, with fatigue being the most common and 
most problematic. The number of side effects and increase 
in side effects reported showed a moderately negative 
correlation with fatigue and depression. Extension of the 
investigation into impact on daily activities revealed a 
significant reduction in self-help (daily) activities as 
side effect burden increased. Negative correlations were 
found between self care (wellness promotion) behaviors and 
fatigue and depression. Forty-two percent of the possible 
correlations between side effect burden and quality of life 
showed a significant negative relationship. These reports 
suggest that side effect incidence does impact distress and 
normal daily activities. Longman, Braden, and Mishel (1997) 
further investigated side effect burden and its implication 
on self-help (daily) activities and self-care (wellness 
promotion) behaviors in women (ü = 53) receiving various 
treatments for breast cancer. The study confirmed that 
fatigue was the most frequent and problematic side effect 
reported over time. Small to moderate negative 
relationships were revealed between difficulty 
concentrating, pain burden, and self-help over time. No 
significant relationship was identified between an increase 
in side effects and self-care behaviors.
Ketiku and Ajekigbe (1990) investigated the incidence
of side effects and quality of life in breast cancer
patients of Nigerian descent. The participants (H = 57)
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receiving CMF for adjuvant therapy or treatment for
metastatic disease reported slight nausea as the most common
side effect. Malaise was reported as moderately severe in a
small number of cases. Other side effects noted were
vomiting, loss of appetite, and menstrual changes. The 
researchers reported no incidence of alopecia in the 
population studied. Ten percent of participants related 
that treatment interfered with their daily activities.
Pharmacological measures implemented to control nausea 
and vomiting need to be considered as having a significant 
effect on the experience of distress related to treatment.
In a randomized, double-blind crossover study, Simmes,
Rhodes, and Madsen (1993) compared the effectiveness of 
prochlorperazine and lorazepam in the management of post 
chemotherapy symptoms. Among the heterogeneous sample 
(Ü = 24) no difference in the amount of nausea and vomiting 
was identified between the two antiemetic regimens.
Patients receiving lorazepam, however, did report less 
fatigue and pain.
Levitt et al. (1993) compared the antiemetic protocols 
of ondansetron and dexamethasone and metoclopramide in 164 
patients receiving CMF for treatment of breast cancer. 
Results of the randomized trial revealed that patients 
receiving dexamethasone and metoclopramide had less nausea 
during the first 24 hours post chemotherapy. Aside from 
this variation, efficacy between antiemetic regimens did not 
differ significantly.
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Gez, Strauss, Vitzheki, Cass, and Edelmann (1992) 
focused on the nausea experienced by breast cancer patients 
(ü = 20) receiving CMF chemotherapy with methylprednisolone 
at two different frequencies: (a) A single dose of 125-mg
methylprednisolone; and (b) two doses of 125-mg, one 2 hours 
prior to CMF treatment and the second immediately before the 
chemotherapy. They found two doses totaling 250-mg of 
methylprednisolone superior to 125-mg dosing without any 
increased incidence or severity of other side effects.
Esvcholoaical and Psvchosocial Variables
Rhodes (1990) has indicated that social support has a
positive effect on health status and can mediate the
patient's experience of post-therapy nausea and vomiting.
According to Rhodes, "social support lessens the effects of
psychosocial and physical stress on an individual by
increasing his or her coping ability" (p. 394). Studies
concerning this association are limited. Picket (1991)
examined the relationship of anticipatory nausea and
vomiting with symptom distress, mood disturbance, stage of
disease, sensitivity to conditioning cues, emetic potential
of antineoplastic drugs, age, psychosocial stress, and
ability to cope. In part Picket's research was based on
Lazarus and Folkman's theory of stress, appraisal and
coping. The heterogeneous sample of 60 adults receiving
chemotherapy in the outpatient setting reported a 32%
incidence of anticipatory nausea with a zero incidence of
anticipatory vomiting. The study revealed that those who
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developed anticipatory nausea received a drug regimen with 
higher emetogenic potential, were younger, and had an 
earlier stage of disease. A high degree of correlation was 
found between anticipatory nausea and emetogenic potential 
of drugs, symptom distress, psychosocial stress, ability to 
cope, and mood disturbance.
Research on the side effect of fatigue has been
performed by Blesch et al. (1991). In a convenience sample
of breast and lung cancer patients (ü = 77) receiving
chemotherapy and radiation, fatigue was reported by 99% of
the participants. Two-thirds of the sample rated fatigue at
moderate to severe levels. Biochemical (laboratory data,
narcotic use, antiemetic use, and active treatment),
physiological (illness stage, treatment history, height,
weight, pain, and performance status), and behavioral
(social support, marital status, employment, psychological
status, and sleep changes) factors were evaluated to
determine those impacting the fatigue experience.
Biochemical factors showed no correlation with fatigue in
the sample as a whole. Evaluation of physiological factors
showed a highly significant correlation between fatigue
intensity and severity of pain in the sample. The
physiological factor of illness duration was correlated with
fatigue in breast cancer patients and the biochemical factor
of total narcotic use had a close to significant
relationship with the fatigue reported by the lung cancer
patients. Psychological status measured by the Profile of
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Mood States revealed significant correlations between the 
scores for tension-anxiety, depression-dejection, and 
fatigue-inertia and fatigue reported in both diagnosis 
groups. Anger-hostility and confusion-bewilderment scores 
were positively correlated with fatigue in lung cancer 
patients while an inverse relationship was noted between 
fatigue in breast cancer patients and vigor-activity scores.
In a study of cancer patients and caregivers, Taylor, 
Baird, Malone, and McCorkle (1993) explored the relationship 
between anger and phase of the cancer trajectory along with 
the relationships to symptom distress, functional status, 
physical caregiver response, depression and demographic 
variables. Findings showed low, stable anger scores in both 
patients (H = 52) and caregivers (H. = 67). Significant 
associations between anger and symptom distress, age, 
depression and church attendance were found. This 
information suggests that manifestations of anger may occur 
in different forms including increased distress from 
symptoms.
Other variables impacting the total symptom experience
have been reviewed in the literature. Richardson (1991)
suggested that self care measures taken by the patient to
meet the demands associated with treatment impact the
symptom experience. She identified knowledge, locus of
control, self concept, socio-economic status, and social
support as correlates of self care practices aimed at
symptom control. Richardson further suggested that the
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meaning associated with the symptoms influences the 
willingness to endure symptoms and the number and type of 
self care measures employed.
In looking at correlates of symptom distress in women 
with lung cancer, Sarna (1993) reported fatigue, frequent 
pain and insomnia as the most prevalent and distressing 
symptoms in the sample (ü = 69). Other common distressing 
problems included poor outlook, dyspnea, and appetite 
disruptions. Higher symptom distress was evident in 
patients with recurrent disease, concurrent respiratory 
disease, previous chemotherapy, absence of previous surgical 
treatment, and low income. Those variables not associated 
with level of distress were (a) level of education, (b) age, 
(c) living alone, (d) religion, (e) type of metastasis,
(f) time since diagnosis, (g) current radiation therapy,
(h) current chemotherapy, (i) site of medical care, and 
(j) concurrent cardiovascular, or (k) musculoskeletal 
disease.
In an extensive study, Tishelman, Taube, and Sachs
(1991) investigated correlates of symptom distress in a
heterogeneous sample (ü = 46) of cancer patients. The
dependent variable of symptom distress was looked at as a
total index as well as divided into sub-indexes: (a) Pain;
(b) appetite and nausea; (c) functional aspects (bowels,
breathing, cough, mobility, and fatigue); (d) psychological
aspects (mood, outlook, insomnia); and (e) social aspects
(appearance, concentration). Independent variables studied
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included demographic, medical/clinical, 
individual/psychosocial, and views of care provided. 
Demographic data was collected on age, marital status, and 
gender. Researchers found significantly higher distress 
related to nausea and appetite reported by three groups of 
patients: (a) women patients; (b) unmarried individuals; and
(c) younger individuals.
Medical or clinical data included (a) diagnosis group,
(b) oncologic treatment with radiation or chemotherapy,
(c) comorbidity, (d) number of weeks from notification of 
cancer diagnosis to cancer registry, (e) disease stage, and 
(f) death information. A significant positive relationship 
was found between oncologic treatment and the total symptom 
distress index as well as the sub-indexes of pain and 
psychological aspects. Higher levels in the sub-index of 
pain corresponded to increasing time after diagnosis. Women 
with breast and gynecological cancers reported less nausea 
and appetite-related distress. Individuals with the 
presence of chronic diseases other than cancer had increased 
distress related to the functional aspects of the illness 
experience. Disease stage was not shown to be statistically 
related to reported distress.
The psychosocial variables under study included sense
of coherence, social relationships, source of support, and
family function. The strongest and most consistent
relationship to symptom distress reported in this study was
the sense of coherence. Sense of coherence involves an
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individual's confidence that (a) internal and external 
stimuli are structured, predictable, and explicable, (b) the 
resources are available to meet the demands imposed by these 
stimuli, and (c) these demands are challenges, worthy of 
investment and engagement. The measure of sense of 
coherence showed a significant negative relationship to the 
total symptom distress index as well as to the psychological 
and social aspects. Social relationships were evaluated 
based on the individual's perception of the source of 
support and the adequacy of that support to nurture and 
enhance the self worth and to aid in problem solving. 
Perceived strength in problem solving was related to less 
distress in functional aspects. Lower feelings of 
nurturance and support of self worth correlated with 
increased distress related to appetite and nausea. Higher 
satisfaction with family function was correlated with more 
distress concerning functional aspects and less distress 
attributed to social aspects.
The individual's view of the care provided by the
health care system encompassed (a) how many doctors they
have seen for treatment, (b) knowledge of which physician is
responsible for the treatment of cancer, (c) satisfaction
with the information received, (d) the health professional's
assessment of individual needs, (e) the satisfaction with
the manner in which they were treated by personnel, and
(f) the perception that the health care personnel had shown
a personal interest in them. A  strong positive association
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was evident between the lack of personal interest from 
health care providers and ratings on the pain sub-index.
The subjects being seem by a more physicians reported higher 
total symptom distress.
In further analysis of the available data, Tishelman 
(1993) revealed few age related differences in symptoms 
distress in the study population. The study data did show 
that younger patients reported more distress in the 
sub-index of appetite and nausea and older patients reported 
increased distress related to mobility.
Coward (1991) explored the concept of 
self-transcendence and it's impact on emotional well-being 
and illness related distress in women with advanced breast 
disease (Ü = 107). Self transcendence was defined as an 
indicator of "becoming as much more as humanly possible 
within the limitations of a particular life situation" 
(Coward, 1991, p. 858). The study found that 
self-transcendence had a direct positive effect on emotional 
well-being and in this manner had an inverse effect on the 
illness distress perceived by the study participants.
To provide information about the breast cancer patient
at risk of developing severe symptom distress, Ehlke (1988)
studied the relationship of symptom distress to disease
stags, chemotherapy protocol, health locus of control,
social support and perception of illness. Using McCorkle
and Young's 13 item symptom distress scale, Ehlke compared
scores for 107 outpatients receiving chemotherapy. Data
22
collection instruments for the independent variables 
included the Multidimensional Health Locus of Control Scale, 
the Norbeck Social Support Questionnaire, and a visual 
analog scale identifying perception of illness. An overall 
analysis of subject experience revealed that fatigue, 
insomnia, nausea, and pain were the top four areas of 
symptom distress in the population studied.
Ehlke (1988) found three significant relationships to 
symptom distress: (a) Symptom distress scores decreased as
the patient's perception of illness became more positive;
(b) as chance health locus of control scores increased, 
symptom distress scores increased; and (c) as internal 
health locus of control scores increased, symptom distress 
scores decreased. The correlation between stage of disease 
and symptom distress approached significance with higher 
distress scores reported by patients as stage of disease 
increased. Those independent variables showing no 
significant correlation with symptom distress scores were 
aggressiveness of chemotherapy (measured by number, dosage, 
and incidence and severity of side effects of chemotherapy 
drugs), powerful others health locus of control, and social 
support scores.
Limitations identified by the researcher were the
convenience sampling method of subject accrual and the lack
of control for antiemetic use. In addition, the nebulous
quantification of the aggressiveness of chemotherapy
resulted in a lack of definitive categories which limited
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the interpretation of this variable's relationship to 
symptom distress scores.
The previous studies have focused on symptom distress
from two related viewpoints: (a) cumulative symptom
distress scores; and (b) distress ratings for individual
side effects associated with chemotherapy treatments. The
research revealed that fatigue, nausea, and appetite changes
are frequent complaints associated with chemotherapy
treatments. Research also reported that patients experience
distress and disruption in lifestyle during the treatment
period. Based on the research cited, no definite
conclusions can be made correlating diagnosis with the
symptom distress experience. Information regarding the
effect of disease stage on symptom distress showed
inconsistent results ranging from no relationship to a
positive relationship. Certain studies suggested that
treatment regimen has some influence on symptom incidence
and the reported distress. Reaching conclusions about
symptom distress is complicated by the variety of
definitions of distress used in the studies. Two levels of
distress can be identified. In some studies, distress has
been identified as the discomfort experienced from the
symptoms associated with treatment. In this
conceptualization, distress is directly related to the
symptom experienced. In other studies, the concept of
distress has been defined in broader terms encompassing
quality of life and disruption in lifestyle. In these
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conceptualizations, distress is associated with the changes 
in the individual's quality of life resulting from the 
symptoms experienced.
Continued research must be conducted to gain a clearer 
understanding of the dynamics of symptom distress in 
patients receiving chemotherapy. Controlling for stage of 
disease and chemotherapy treatment, this partial replication 
of the Ehlke (1988) study will explore the relationships 
between symptom distress and health locus of control, 
perception of illness, perception of treatment efficacy and 
social support.
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CHAPTER 3 
METHODS
Design
The purpose of this study was to describe the 
relationship between symptom distress and health locus of 
control, perception of illness, perception of treatment 
efficacy, and social support. A prospective descriptive 
correlational design was used. The prospective design 
involved the examination of the presumed mediating variables 
(health locus of control, perception of illness, perception 
of treatment efficacy, and social support) in relationship 
to the presumed effect or outcome (symptom distress). 
Knowledge of these relationships lends itself to clinical 
application and provides the groundwork for further 
research. Limitations inherent in the descriptive 
correlational design stem from the lack of control over the 
independent variables. There was no experimental 
manipulation of independent variables nor random assignment 
of subjects to different groups. Relationships can be 
explored; however, causal inferences can not be made.
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Sample and Setting
Subjects for this study were selected from women with
stage one breast cancer receiving weekly or day 1/day 8 CMF
as adjuvant chemotherapy in the outpatient setting.
A convenience sample of 36 women were invited to 
participate. Thirty-three women consented to participate in 
the study and completed the data collection. Subjects were 
completing the second month of treatment in the CMF protocol 
with no prior exposure to other chemotherapy protocols. In 
addition, the subjects were 18 years old or older, alert and 
oriented to person place and time, and able to read and 
write English.
Subjects were excluded from this study if their 
treatment history for the current diagnosis included
radiation therapy or if they were receiving concomitant
radiation therapy.
Instruments
The dependent variable of symptom distress was measured
using the Symptom Distress Scale (SOS) developed by McCorkle
and Young (1978) (Appendix A). The self-report scale
contains 13 items to evaluate common symptoms of concern to
patients. The symptoms include: nausea, outlook, appetite,
insomnia, pain, fatigue, bowel pattern, concentration,
appearance, breathing, and cough. Each symptom is rated on
a 5-point Likert-type scale ranging from one (no distress)
to five (extensive distress). Descriptive words at each
point on the scale serve to operationalize the item and
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enhance validity. The 13 items can be summed to provide the 
total symptom distress ranging from 13 to 65. Higher scores 
denote greater levels of symptom distress. The SDS has a 
reported reliability coefficient alpha of .82 in 53 patients 
receiving chemotherapy or radiation therapy. Internal 
consistency of the SDS in the current study was alpha = .89.
The intervening variables of health locus of control, 
social support, perception of illness, and perception of 
treatment efficacy were measured as follows. Personal 
control was measured using the Multidimensional Health Locus 
of Control (MDHLC) scale developed by Wallston, Wallston, 
and DeVellis (1978) (Appendix B ) . The MDHLC scale is an 18 
item instrument designed to measure beliefs about the source 
of reinforcement for health related behaviors. Three 
subscales of personal control beliefs are depicted in the 
tool: (a) internal (IHLC); (b) powerful others (PHLC); and
(c) chance health locus of control (CHLC). The items are 
measured on a 6-point Likert scale ranging from one 
(strongly disagree) to six (strongly agree). Each subscale 
is scored by summing the responses to the items contained in 
that subscale. Possible scores on each subscale range from 
6 to 36. Using two combined forms of the scale on a 
convenience sample of adults, alpha reliabilities for each 
subscale were reported: (a) IHLC = .859; (b) PHLC = .830;
and (c) CHLC = .841. (Wallston, Wallston, and DeVellis, 
1978). The alpha coefficients for this study were
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IHLC = .744, PHLC = .565, and CHLC = .539. The low alpha 
coefficients obtained with this sample population may be 
explained by the small sample size.
Construct validity of each subscale has been 
established based on Pearson's R calculations. The IHLC and 
PHLC subscales are statistically independent (r = .124).
The IHLC and CHLC are negatively correlated 
(r = -.293, p < .05). The external subscales, PHLC and 
CHLC, are positively correlated (r = .204, p < .05). These 
subscale relationships provide evidence that the MDHLC scale 
does distinguish internal and external control 
characteristics. Based on Levenson's (1973) internal (I), 
powerful others (P), and chance (C) locus of control scales, 
concurrent validity has been reported. Each subscale of 
the MDHLC scale correlates most highly with its theoretical 
counterpart of Levenson's scales. Correlations between 
health status and MCHLC scales help establish initial data 
on predictive validity. Health status was positively 
correlated with IHLC (r = .403, p < .001), and negatively 
correlated with CHLC (r = -.275, p < .01). Health status 
showed no correlation with PHLC (r = -.055). (Wallston, 
Wallston, and DeVellis, 1978)
Perception of social support was measured using the
Norbeck Social Support Questionnaire (Norbeck, Lindsey, &
Carrieri, 1981) (Appendix C ) . This instrument is a self
report questionnaire measuring three components of social
support: (a) total network; (b) total function; and
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(c) total loss. The functional properties of social support 
include (a) affect, the expression of positive feelings of 
one person to another, (b) affirmation, endorsement of 
another's behaviors, perceptions, or expressed views, and
(c) aid, the giving of symbolic or material aid to another. 
Respondents are asked to list persons who provide personal 
support and their relationship to the respondent.
Functional aspects of each relationship are evaluated by the 
respondent using a 5-point Likert rating scale. Finally, 
information concerning recent losses of important 
relationships is collected.
Each functional subscale and network property subscale 
had a high degree of test-retest reliability. The 
test-retest correlations for these subscales ranged from .85 
to .92. High levels of internal consistency have been 
established based on intercorrelations among all items.
Alpha correlations for each subscale were reported:
(a) affect = .97; (b) affirmation = .96; (c) aid = .89.
(Schaefer, Coyne, & Lazarus, 1981). The alpha coefficients 
for this study were affect = .97, affirmation = .97, and 
aid = .96.
Moderate levels of concurrent validity have been 
established through intercorrelations with the social 
support questionnaire developed by Coyne and Lazarus 
(Schaefer, Coyne, & Lazarus, 1981). Initial construct 
validity was questionable when tested against the Profile of
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Mood States and the Sarasen Life Experiences Survey.
(Norbeck, Lindsey, & Carrieri, 1981)
Further testing (Norbeck, Lindsey, & Carrieri, 1983) to 
establish concurrent validity revealed medium levels of 
association (range: r = .35 to .41) between the functional 
components of NSSQ and the Personal Resource Questionnaire 
(PRQ) (Brandt & Weinert, 1981). Association was also 
demonstrated between network properties of NSSQ and PRQ 
(range: r = .24 to .32). Construct validity was
demonstrated by significant correlations between network 
property items and functional items of the NSSQ and the 
Fundamental Interpersonal Relations Orientation (FIRO-B) 
constructs of need for inclusion (range: r = .17 to .26)
and need for affection (range: r = .15 to .27). Predictive
validity data revealed that aid and duration of 
relationships have significant interaction effects on the 
outcome of negative mood and reflects a stress buffering 
role of social support. (Norbeck, Lindsey, & Carrieri,
1983).
The subject's perception of the illness was measured 
with a 100 millimeter visual analog scale designed by Ehlke 
(1988) (Appendix D). Subjects were asked to respond to the 
question "How stressful has this illness been to you?" by 
placing an "x" on the scale where it best represents how 
they feel. Anchors were (a) this is the best thing that has 
happened to me, and (b) this is the worst thing that has 
happened to me.
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The subject's perception of treatment efficacy was 
measured using a 100 millimeter visual analog scale 
(Appendix E) . Subjects were asked to respond to the 
question "How effective are your chemotherapy treatments in 
fighting your cancer?" by placing an "x" on the scale where 
it best represents how they feel. Anchors were (a) not 
effective and (b) extremely effective.
A demographic data form was utilized to obtain 
descriptive information about the subjects (Appendix F ) .
A chart review form was utilized to obtain information 
relevant to the chemotherapy protocol the patient is 
receiving (Appendix G ) . To assist in tool identification, 
data collection tools will be color coded co distinguish 
each form being used.
Procedure
Application was made to the Grand Valley State 
University Human Research Review Committee for approval. 
Approval was also obtained from the Research Committee of 
Holland Community Hospital as well as physicians in the 
office where subject recruitment occurred. Once approval 
from the above agencies had been obtained, subject 
recruitment and data collection proceeded.
Recruitment of subjects occurred in the identified 
office based outpatient oncology clinic. Identification of 
subjects who met basic eligibility criteria occurred through 
chart review by the nursing staff at the identified office.
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The researcher then reviewed the patient's chart to confirm 
that the patient met the subject criteria.
Once eligible subjects had been identified, the 
researcher made personal contact with each subject on week 
7 of treatment to briefly explain the nature of the research 
and the process for data collection. The subject was given 
the opportunity to read the consent form (Appendix H) 
privately, after which the researcher returned to answer any 
questions. Once consent was obtained, one copy of the 
signed form was placed in the subject's chart, one copy 
given to the subject, and the final copy retained by the 
researcher. The subject was advised to plan 30 minutes in 
addition to their appointment for week 8 of chemotherapy to 
complete the Multidimensional Health Locus of Control Scale, 
the Norbeck Social Support Questionnaire, and the patient 
perception visual analog scales.
On week 8, the researcher completed the chart review
form. The researcher interviewed the subject using the
demographic data form. The subject completed the
Multidimensional Health Locus of Control Scale, the Norbeck
Social Support Questionnaire, and the patient perception
visual analog scales. The researcher was available if
questions arose related to completion of the tools. The
Symptom Distress Scale (SDS) was given to the subject.
Based on data collected by Greene, Nail, Fieler, Dudgeon,
and Jones (1994) reporting increased side effects 2 days
post treatment, subjects were requested to complete the SDS
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in the privacy of their home 2 days after week 8 of 
treatment. An estimated ten minutes was required to 
complete the SDS. To enhance confidentiality, data 
collection forms were coded by number and subjects were 
instructed not to identify rhemselves on any of the 
questionnaires completed during the study. An index of 
subjects with the associated code number was kept in a 
locked file. Subjects were requested to mail the SDS back 
to the researcher in a stamped, addressed envelope that was 
provided. If the SDS was not received by the researcher 
within 10 days of being given to the subject, a follow-up 
phone call to the subject was made. Upon receipt of the 
completed form, the information associating the subject with 
the code number was destroyed. If requested at the time of 
informed consent, results of the study were mailed to the 
subject at the completion of the study.
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Table 1
Time Line of Interaction with Subjects
Time Activity
Week 7 Identify subject
Obtain consent
Week 8 Complete:
Chart review form
Demographic data form
Health Locus of Control Scale
Norbeck Social Support Questionnaire
Visual analog scales
Provide SDS for completion at home
2 days after Subject completes SDS and mails back to
week 8 appt
the researcher
10 days after Follow-up call if SDS not received by
week 8 appt
researcher.
The researcher recognized the potential risk of subject 
fatigue when completing the questionnaires. To prepare the 
patient, the time line allowed for the subject to be 
notified at the time of informed consent of the additional 
time required for week 8 of treatment. The study design 
allowed for completion of the SDS in the subject's home 
which allowed the subject to rest as needed.
35
CHAPTER 4 
DATA ANALYSIS
The intervening variables of personal control, 
perception of illness, perception of treatment efficacy, and 
social support are measured at the interval level producing 
a total score for the components of each variable. The 
dependent variable of symptom distress is measured at the 
interval level for the total score. The Pearson correlation 
coefficient is used to determine the relationship between 
symptom distress and health locus of control, perception of 
illness, perception of treatment efficacy, and social 
support. Relationships were considered to be significant at 
the 0.05 level. The strategy used to handle missing data 
was the substitution of the mean value on the variable for 
those cases with missing values (Polit & Hungler, 1994).
All data were analyzed using the SPSS/PC package. 
Characteristics Qt Subjects
Identification of potential subjects for the study was 
made over a one and one-half year period. The initial 
criteria for inclusion in the study was weekly CMF only.
Due to difficulties with subject accrual, the criteria was 
extended to include those women receiving day 1/day 8 CMF.
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The sample of 33 women ranged in age from 36 to 7 8 
years of age. The mean age was 50.54, with a standard 
deviation of 10.71. Subjects were predominantly Caucasian 
(97% Caucasian, 3% asian) and well-educated. The 
distribution of the sample by education is shown in Table 2. 
Table 2
Distribution of Sample bv Education.
Characteristic Frequency
Group
Percentage
Less than High School 2 6.1
High School 8 24 .2
Partial College 13 39.4
College 3 9.1
Beyond 4 years of College 7 21.2
Total 33 100.0
A relatively high percentage of subjects reported 
identification with the Dutch culture. The breakdown of 
subjects according to cultural identification is shown in 
Table 3.
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Table 3
Distribution of Sample by Ethnicity
Characteristic
Group
Frequency Percentage
Dutch 13 39.4
Southern 1 3.0
Hispanic 1 3.0
Italian 1 3.0
French 1 3.0
Japanese 1 3.0
German 1 3.0
Polish 1 3.0
Irish 1 3.0
None 12 36.4
Total 33 100.0
The types of occupations of the women in the sample 
included professional (21.2%), technical (3.0%), clerical 
(27.3%), industrial (9.1%), entrepreneur (9.1%), and 
missionary (3.0%) with 27,1% of the sample reporting no 
occupation. The range of hours worked per week was zero 
(42.4%) to forty (24.2%). The mean number of hours worked 
per week was 18.75, with a standard deviation of 17.90.
A review of past and present significant health 
problems revealed that 30.3% could identify no health
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problems they viewed as significant, 66,7% identified at 
least one significant health problem, and 6.1% identified 
three significant health problems. Comorbid conditions 
identified in the sample included arthritis, congestive 
heart failure, diabetes, emphysema, hepatitis, migraines, 
hypertension, graves disease, hypothyroidism, gallbladder 
disease, and sleep apnea. At least one comorbidity was 
identified in 48.5% of the sample with a small percentage 
(6.1%) with three comorbid conditions.
Essentially all of the sample population received 
surgical intervention prior to chemotherapy treatments. 
Distribution of sample by surgical intervention is reported 
in Table 4.
Table 4
Distribution of SampleJby Surgical Intervention
Characteristic Frequency
Group
Percentage
Lumpectomy 16 48.5
Modified Mastectomy 10 30.3
Mastectomy with Reconstruction 7 21.2
Total 33 100.0
Cumulative drug doses were calculated and reported as 
follows: (a) cyclophosphamide, range = 3450-mg to 7 650-mg,
mean = 5096.97-mg, SO = 950.98; (b) methotrexate.
39
range = 75-mg to 340-mg, mean = 198.15-mg, SD = 63.37;
(c) fluorouracil, range = 2100-mg to 5350-mg, 
mean = 4083.63-mg, SD = 657.47. Twenty-three subjects, or 
69.7% of the sample, received their treatments on a weekly 
basis, while the remaining 10 subjects, or 30.3% received 
their treatments on a day 1/day 8 schedule. Antiemetics 
were available to 100% of the study population with 87.9% 
reporting antiemetic usage at some point in their 
chemotherapy treatments. Pain medications were available to 
60.6% of the sample with one third reporting usage.
Out of a possible symptom distress score ranging from 
13 to 65, the study subjects revealed a mean symptom 
distress score of 22.86 with a standard deviation of 7.15. 
With higher scores indicating greater symptom distress, 
analysis of SOS scores in the sample revealed low to medium 
distress associated with the CMF protocol for adjuvant 
treatment of breast cancer.
The subjects were administered the Multidimensional
Health Locus of Control Scale (MDHLC) which encompasses
three personal control beliefs: (a) internal (IHLC);
(b) powerful others (PHLC); and (o) chance (CHLC) health
locus of control. The items pertaining to each of the three
subsoales of personal control beliefs when summed have a
potential to range from 6 to 36 with higher scores
reflecting a stronger belief in the control of that
particular source of reinforcement for health related
behaviors. The mean scores and the standard deviations for
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the MDHLC subscales are shown in Table 5. The sample 
population showed an overall higher belief that the 
individual can control or shape the outcome of events and 
less belief in this control resting in others.
Table 5
Mean Scores of the MDHLC Subscales
Scale/Subscales
Score
n 2R
IHLC 24.43 5.28
CHLC 16.46 4.28
PHLC 18 . 00 5.01
The Norbeck Social Support Questionnaire (NSSQ) 
includes the subscales of emotional support with a possible 
range of scores of 0 to 384, and tangible support with a 
possible range of 0 to 192. Sample responses for tangible 
support ranged from 34 to 156 with a median score of 64. 
Sample responses for emotional support ranged from 77 to 358 
with a median of 189. The mean scores and standard 
deviations for the NSSQ and selected subscales are shown in 
Table 6.
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Table 6
Mean Scores of the NSSQ and Subscales
Scale/Subscales
Score
2R
NSSQ Total 278.46 116.60
Tangible Support 80.00 36. 99
Emotional Support 200.82 81.85
The sample results concerning perception of illness
revealed a mean of 62.09 with a 3D of 23.03. Responses
ranged from 12 to 100 with a median of 59. Using the median 
split of the sample to evaluate perception, individuals with 
scores below the median indicate a more positive view of 
their illness and those with scores above the median a more 
negative view of their illness. Perception of treatment
efficacy scores reported a mean of 76.57 with a standard
deviation of 18.04. The perception of treatment efficacy 
scores ranged from 35 to 100 with a median of 77.5. Higher 
perceptions of treatment efficacy are associated with scores 
above the median with lower perceptions of treatment 
efficacy revealed in scores below the median.
Study Question
Pearson coefficients were used to answer the study 
question: Is there a relationship between symptom distress
and health locus of control, perception of illness.
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perception of treatment efficacy, and social support? The 
reported coefficients are shown in Table 7. The lack of 
significant correlations indicates that there is no 
identifiable relationship between symptom distress and 
personal control, perception of illness, perception of 
treatment efficacy, and social support. With no 
relationship between the variables established, a multiple 
regression analysis would not add value to the discussion 
and was therefore deferred.
Table 7
Correlations with Symptom Distress
Independent Variable Coefficient Significance
IHLC -,24 ,20
CHLC ,33 . 08
PHLC ,10 , 61
Aid -,01 , 94
Emotional Support .08 , 66
Total Support , 12 , 56
Perception of Illness ,21 ,27
Perception of Treatment Efficacy -,34 , 09
Hypotheses
Using T-tests for equality of means to test the study 
hypotheses confirmed the absence of relationship between the 
independent variables and symptom distress.
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Hypothesis 1: Individuals with higher internal health
locus of control scores will have lower symptom distress 
scores was not supported (t = .93; df = 26; p = .36).
Hypothesis 2: Individuals with more positive
perceptions of illness scores will have lower symptom 
distress scores was not supported
(t = -.88; df = 27; p = .39).
Hypothesis 3: Individuals with more positive
perceptions of treatment efficacy will have lower symptom 
distress scores was not supported
(t = 1.98; df = 27; p = .06). Although these results
approached significance the relationship does not prove to
be strong enough to lend predictive value to the hypothesis.
Hypothesis 4: Individuals with higher social support
scores will have lower symptom distress scores was not 
supported (t = .00; df = 21; p = .99).
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CHAPTER 5 
DISCUSSION AND IMPLICATIONS
Discussion
This study was designed to examine the relationship 
between symptom distress and health locus of control, 
perception of illness, perception of treatment efficacy, and 
social support in breast cancer patients receiving 
cyclophosphamide, methotrexate, and fluorouracil as adjuvant 
chemotherapy in the outpatient setting. McCorkle and Young 
(1978) recognized symptom distress as a subjective 
experience whose expression is dependent on the individual's 
perception. In a heterogeneous sample in relationship to 
chemotherapy regimen and disease stage, Ehlke (1988) was 
able to document significant relationships between symptom 
distress and perception of illness, chance health locus of 
control, and internal health locus of control. Controlling 
for disease stage and chemotherapy regimen this study 
attempted to replicate these findings. The findings of this 
study revealed no statistically significant relationships 
between symptom distress and health locus of control, 
perception of illness, perception of treatment efficacy, and 
social support in the study population.
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Although no effort was made to identify the role of 
cultural tendencies in the response to illness, the cultural 
influences identified by the study population showed a 
predominance of dutch associations. This is thought to be 
reflective of the geographic location from which the sample 
was collected. While 72.9% of the sample reported an 
occupational history, few subjects (24.2%) reported 
maintaining a 40 hour work week during their treatment 
period with some reporting to the researcher that they were 
not working at that time due to their illness and treatment. 
This indicates the need to focus on self care and recovery 
during the treatment period.
Although direct correlations between symptom 
distress and comorbid conditions were not the attempt of 
this study, reported comorbidity was included to provide 
information about the sample population. Given the report 
of no comorbid conditions in the majority (51.5%) of the 
study population, the researcher believes that comorbidity 
does not confound the symptom distress scores reported by 
the study participants.
The availability and usage of antiemetics and pain
medication allow for the individual to take personal control
of the symptoms that can occur with treatment and could
impact the amount of distress associated with treatment. It
is important to note that usage of antiemetics by 87.9% of
the sample during the chemotherapy treatments provides
evidence to support the researchers conclusion that the
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sample has an overall higher belief that the individual can 
control or shape the outcome of events.
The study participants reported low to medium distress 
after treatment with CMF. This may indicate that the CMF 
protocol is associated with a mild side effect profile. The 
low distress scores may also be due to a selection bias 
inherent in the voluntary nature of subject accrual. Two to 
three eligible subjects declined to participate in the study 
due to a stated inability to cope with an additional 
stressor. Results may have been impacted by exclusion of 
those experiencing more distress.
Reports of illness perception and perception of 
treatment efficacy may be influenced by a number of factors. 
Individual's experiences and encounters with other 
individuals receiving chemotherapy regardless of diagnosis 
may impact the participants evaluation of their treatment 
experience. Ratings concerning perception of treatment 
efficacy could be based on specific information shared by 
the health care team, the participants recall and belief in 
the information presented, or a generalized hopefulness 
inherent in the individual. On a societal level information 
has been widely disseminated related to cancer, its 
treatment, potential side effects, and the increasing 
frequency of positive outcomes.
The findings of this study did not identify a
correlation between symptom distress and health locus of
control, perception of illness, perception of treatment
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efficacy, and social support. The low to medium reports of
symptom distress may have made it difficult to make
correlations with potential mediating factors.
Limitations of the Study
Although the study is designed to control for threats
to validity, there remain three major threats to the
generalizability of the study. The performance of the
subjects may have been affected by the subject's perception
of the researcher's expectations. Recognizing the
researcher's interest in the study, subjects may have
answered the questions in the manner they thought the
researcher expected them to be answered. To reduce this
threat the introductory statement by the researcher was
brief and simple, avoiding any reference to expected
relationships. The small sample size was a limitation to
the study. Finally, the generalizability of the study
results to a larger target population may also be limited
due to the use of a convenience sample from this particular
geographical location. Using the CMF protocol as an
inclusion criteria way be considered a limitation of the
study. As discussed above the mild side effect profile
associated with the CMF protocol may have made correlations
between variable difficult to establish.
Implications for Nursing Practice
Because the hypotheses of relationships between the
independent variables and symptom distress were not
supported in the study assumptions can not be made related
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to individual experiences. Important information to note is 
the identification of low to medium symptom distress 
reported by the subjects receiving CMF regardless of the 
independent variables identified_in the study. Nursing 
practitioners can use the mild side effect profile reported 
as a guide in preparing individuals for the chemotherapy 
experience. Information and encouragement can be given 
related to the expected experience with deviations from the 
expected response addressed on a case by case basis. 
Recommendations for Future Research
Although no statistically significant relationship was 
identified between symptom distress and health locus of 
control, perception of illness, perception of treatment 
efficacy, and social support, this does not preclude further 
investigation of the possible correlation between these 
variables in other populations. Application of the study 
design to a larger study population as well as populations 
receiving different chemotherapy protocols for different 
cancer diagnoses may prove advantageous. As investigation 
into the variables influencing symptom distress continues 
consideration of spirituality as it relates to distress is 
suggested.
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APPENDICES
APPENDIX A 
Symptom Distress Scale
ID# DATE
(SDS) Each of the following sections lists 5 different 
statements. Think about what each statement says, then 
place a circle around the one statement that most closely 
indicates how you feel 2 days after treatment. Please 
circle one statement for each section.
1. Appetite
1 I have my normal appetite
2 My appetite is usually, but not always, pretty 
good
3 I don't really enjoy my food like I used to
4 I have to force myself to eat my food
5 I cannot stand the thought of food
2. Insomnia
1 I sleep as well as I always have
2 I have occasional spells of sleeplessness
3 I frequently have trouble getting to sleep and 
staying asleep
4 I have difficulty sleeping almost every night
5 It is almost impossible for me to get a decent 
night's sleep
3. Pain (a)
1 I almost never have pain
2 I have pain once in a while
3 I frequently have pain - several times a week
4 I am usually in some degree of pain
5 I am in some degree of pain almost constantly
4. Pain (b)
1 When I do have pain, it is very mild
2 When I so have pain, it is mildly distressing
3 The pain I do have is usually fairly intense
4 The pain I have is usually very intense
5 The pain I have is almost unbearable
Please go to next page
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ID#_______ DATE_____________
5. Fatigue
1 I am usually not tired at all
2 I am occasionally rather tired
3 There are frequently periods when I am quite tired
4 I am usually very tired
5 Most of the time, I feel exhausted
6. Bowel
1 I have my normal bowel pattern
2 My bowel pattern occasionally causes me some 
discomfort
3 I frequently have discomfort from my present bowel 
pattern
4 I am usually in discomfort because of my present 
bowel pattern
5 My present bowel pattern has changed drastically 
from what was normal for me
7. Concentration
1 I have my normal ability to concentrate
2 I occasionally have trouble concentrating
3 I often have trouble concentrating
4 I usually have at least some difficulty
concentrating
5 I just can't seem to concentrate at all
8. Appearance
1 My appearance has basically not changed
2 My appearance has gotten a little worse
3 My appearance is definitely worse than it used to 
be, but I am not greatly concerned about it
4 My appearance is definitely worse that it used to 
be, and I am concerned about it
5 My appearance has changed drastically from what it 
was
Please go to next page
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ID# DATE
10
Breathing
1 I usually breathe normally
2 I occasionally have trouble breathing
3 I often have trouble breathing
4 I can hardly ever breathe as easily as I want
5 I almost always have severe trouble with my
breathing
Outlook
1 I am not fearful or worried
2 I am a little worried about things
3 I am quite worried, but unafraid
4 I am worried and a little frightened about things
5 I often have persistent and severe coughing spells
11. Cough
1
2
3
4
I seldom cough 
I have an occasional cough 
I often cough
I often cough, and occasionally have severe 
coughing spells
I often have persistent and severe coughing spells
12. Nausea a
1 I seldom feel any nausea at all
2 I am nauseous once in a while
3 I am often nauseous
4 I am usually nauseous
5 I suffer from nausea almost continually
13. Nausea b
1
2
3
4
5
When
When
When
When
When
I do have nausea, it is very mild 
I do have nausea, it is mildly distressing 
I have nausea, I feel pretty sick
I have nausea, I feel very sick
I have nausea, I am as sick as I could
possibly be
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APPENDIX B
Multidimensional Health Locus of Control Scale 
MHLC Form A
This is a questionnaire designed to determine the way in 
which different people view certain important health-related 
issues. Each item is a belief statement with which you may 
agree or disagree. Becide each statement s a scale which 
ranges from strongly disagree (1) to strongly agree (6).
For each item we would like you to circle the number that 
represents the extent to which you disagree or agree with 
the statement. The more strongly you agree with a 
statement then the higher will be the number you circle.
The more strongly you disagree with a statement then the 
lower will be the number you circle. Please make sure that 
you answer every item and that you circle only one number 
per item. This is a measure of your personal beliefs; 
obviously, there are no right or wrong answers.
Please answer these items carefully, but do not spend too 
much time on any one item. As much as you can, try to 
respond to each item independently. When making your 
choice, do not be influenced by your previous choices. It 
is important that you respond according co your actual 
beliefs and not according to how you feel you should believe 
or how you think we want you to believe.
SD = Strongly Disagree 
MD = Moderately Disagree 
D = Slightly Disagree 
A = Slightly Agree 
MA = Moderately Agree 
SA = Strongly Agree
1. If I get sick, it is my own behavior which determines 
how soon I get well again.
SÜ m  D. A HA 2A
1 2 3 4 5 6
2. No matter what I do, if I am going to get sick, I will 
get sick.
Sn HÛ Ü A HA SA
1 2 3 4 5 6
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3. Having regular contact with my physician is the best way 
for me to avoid illness.
sn tin n a tiA sa
1 2 3 4 5 6
4. Most things that affect my health happen to me by 
accident.
sn tin n a tiA sa
1 2 3 4 5 6
5. Whenever I don't feel well, I should consult a medically 
trained professional.
sn tin n a ha sa
1 2 3 4 5 6
6. I am in control of my health.
sn tin n a tiA sa
1 2 3 4 5 6
7. My family has a lot to do with my becoming sick or 
staying healthy.
sn tin n a tiA sa
1 2 3 4 5 6
8. When I get sick, I am to blame.
sn tin n a tiA sa
1 2 3 4 5 6
9. Luck plays a big part in determining how soon I will 
recover from an illness.
sn tin n a tiA sa
1 2 3 4 5 6
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10. Health professionals control my health.
sn tin n A M6. SA
1 2 3 4 5 6
11. My good health is largely a matter of good fortune.
sn tin n a. tia. sa
1 2 3 4 5 6
12. The main thing which affects my health is what I myself 
d o .
sn tin n a tiA sa
1 2 3 4 5 6
13. If I take care of myself, I can avoid illness.
sn tin n a tiA sa
1 2 3 4 5 6
14. When I recover from an illness, it's usually because 
other people (for example, doctors. Nurses, Family, 
friends) have been taking good care of me.
sn tin n a tiA sa
1 2 3 4 5 6
15. No matter what I do. I'm likely to get sick.
sn tin n a tiA sa
1 2 3 4 5 6
16. If it's meant to be, I will stay healthy.
sn tin n A tiA sa
1 2 3 4 5 6
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17. If I take the right action, I can stay healthy,
SÜ MU Û. A MA SA
1 2 3 4 5 6
18, Regarding my health, I can only do what my doctor tells 
me to do,
SÜ MR Ü A MA SA
1 2 3 4 5 6
56
APPENDIX C 
Norbeck Social Support Questionnaire
SOCIAL SUPPORT QUESTIONNAIRE
PLEASE READ ALL DIRECTIONS 
ON THIS PAGE BEFORE STARTING.
Please list each significant person in your life on the 
right, consider all the persons who provide personal 
support for you or who are important to you.
Use only first names or initials, and then indicate the 
relationship, as in the following example:
Example :
First name or Initials Relationship
 1--------- Mary T.  ___ Friend_____
2 ._________Bob_________ Brother
3._________M.T.-------- Mother_____
4 .______________________________    Friend____
5._________Mrs. R. Neighbor
etc.
Use the following list to help you think of the people 
important to you, and list as many people as apply in your 
case.
-spouse or partner
-family members or relatives
-friends
-work or school associates 
-neighbors
-health care providers 
-counselor or therapist 
-minister/priest/rabbi 
-other
You do not have to use all 24 spaces. use as many spaces as 
you have important persons in your life.
1980 by Jane S. Norbeck, D.N.Sc. 
University of California, San Francisco 
Revised 1982 
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Page 1
PERSONAL NETWORK
1 .  1 ._____________________________
2.  2._______________________________
3  .____________________________ 3._______________________________
4  .____________________________ 4._______________________________
5  .____________________________ 5._______________________________
6 .  6._______________________________
7  .____________________________ 7._______________________________
8  .  8._______________________________
9.____________________________ 9._______________________________
10.  10._______________________________
11.  11._______________________________
12.  12._______________________________
13 .____________________________ 13._______________________________
14 .____________________________ 14._______________________________
15 .____________________________ 15._______________________________
16 .  16._______________________________
17 .____________________________ 17._______________________________
18 .  18._______________________________
19 .___________________________  19._______________________________
20 .  20._______________________________
21.  21._______________________________
22.  22._______________________________
23 .___________________________  23._______________________________
24.  24 .
WHEN YOU HAVE FINISHED YOUR LIST, PLEASE TURN TO PAGE 2.
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Page 2
For each person you listed, please answer the following 
questions by writing in the number that applies.
1 = not at all
2 = a little
3 = moderately
4 = quite a bit
5 = a great deal
Question 1: Question 2
How much does this person 
make you feel liked or 
loved?
How much does this person 
make you feel respected 
or admired?
1.
2.
3.'
4 .
5 V 
6 .
7.'
8 .' 
9.
10 .■ 
1 1 .' 
1 2 .' 
13.' 
14 .'
15.'
16.'
17.'
18.
19.'
20 .' 
21.' 
22.
23.
24.
1 .
2.
3.
4 .'
5.
6.
7.' 
8 .
9.'
1 0 .'
1 1 .'
1 2 .'
13.'
14.'
15.'
16.'
17.'
18.
19.'
20. 
2 1 .' 
22.
23.
24 .
GO ON TO NEXT PAGE
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Page 3
1 =  
2 =
3 =
4 = 
q =
Question 3:
not at all 
a little 
moderately 
quite a bit 
a great deal
Question 4:
How much can you confide 
in this person?
How much does this person 
agree with or support your 
actions or thoughts?
1 .
2.
3.'
4.
5/ 
6 .
7.
8 .' 
9.
1 0 .'
1 1 .'
1 2 .'
13.'
14.'
15.'
16.'
17.'
18.'
19.
20 .' 
2 1 .' 
22.
23.
24.
1
2 ,
3,
4
5,
6 ,
7,
8 , 
9,
1 0 , 
1 1 , 
1 2 , 
13, 
14 ,
15,
16,
17,
18,
19,
20 , 
2 1 , 
22
23,
24,
GO ON TO NEXT PAGE
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Page 4
Question 5:
1 = not at all
2 = a little
3 = moderately
4 = quite a bit
5 = a great deal
Question 6:
If you needed to borrow 
$10, a ride to the doctor, 
or some other immediate 
help, how much could this 
person usually help?
If you were confined to
bed for several weeks,how much
could this person help you?
1 .
2 ,
3.
4,
5,
6 .
7,
8, 
9,
1 0 .
11,
12 .
13.
14.
15.
16.
17.
18.
19.
2 0 . 
2 1 . 
22,
23.
24.
1 .
2.
3.
4
5.'
6.
7.'
8
9.
1 0 .' 
1 1 .' 
12. 
13.' 
14 .'
15.'
16.'
17.'
18.'
19.'
20.' 
2 1 .' 
22 .
23.
24.
GO ON TO NEXT PAGE
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Page 5
Question 7:
How long have you known 
this person?
Question 8:
How frequently do you 
usually have contact with 
this person? (Phone 
calls, visits, or 
letters)
1 = less than 6 months
2 = 6 to 12 months
3 = 1 to 2 years
4 = 2 to 5 years
5 = more that 5 years
5 = daily
4 = weekly
3 = monthly
2 = a few times a year
1 = once a year or less
1 , 
2 , 
3, 
4 ,
5,
6 ,
7,
8 , 
9.
1 0 , 
1 1 , 
1 2 , 
13, 
14 ,
15,
16,
17,
18.
19,
20. 
2 1 , 
2 2 ,
23,
24.
1
2
3
4 , 
5, 
6
7
8 
9,
1 0 , 
1 1 , 
1 2 , 
13, 
14 ,
15,
16,
17,
18,
19,
20 , 
2 1 , 
22
23,
24,
PLEASE BE SURE YOU HAVE RATED EACH PERSON 
ON EVERY QUESTION. GO ON TO THE LAST PAGE.
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9. During the past year, have you lost any important
relationships due to moving, a job change, divorce or 
separation, death, or some other reason?
 0. No
1. Yes
IF YES:
9a. Please indicate the number of persons from each 
category who are no longer available to you.
 spouse or partner
 family members or relatives
 friends
 work or school associates
 neighbors
 health care providers
 counselor or therapist
 minister/priest/rabbi
 other (specify)_______________________
9b. Overall, how much of your support was provided by 
these people who are no longer available to you?
 0. none at all
 1. a little
 2. a moderate amount
 3. quite a bit
 4. a great deal
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APPENDIX D
Perception of Illness
How stressful has this illness been to you? 
(Put an X somewhere on the line below).
This is This is
the best the
thing worst
that has ----------------------------------------------  thing
happened that has
to me. happened
to me.
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APPENDIX E
Perception of Treatment Efficacy
How effective are your chemotherapy treatments 
in fighting your cancer?
(Put an X somewhere on the line below).
Not   _____________________________________________ Extremely
Effective Effective
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APPENDIX F
Demographic Data
1. Age: ___________ years (to the nearest year]
2. Race:
 1____Caucasian
 2____Black
 3____Hispanic
 4____Asian
 5____Native American
 6____Other (please identify) ______________
Highest level of education completed:
 1____Less than high school
 2____High school
 3 Partial college education (3 years or less)
 4____College education (4 years)
 5____Beyond 4 years of college
Which ethnic group do you identify with?
6. Occupation:
7. Hours of work outside the home: _____________hrs/week
8. What health problems, past or present, have you
experienced that you consider significant?
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APPENDIX G
Chart Review Form
1. Chemotherapy Treatment— starting with initial closes as 
indicated and titrated weekly to achieve white blood count 
between 2.5 - 3.0 and platelet count above 100.
Drug Dosage
Initial Cumulative
Cyclophosphamide ________ ______________
DO, (lOOmg continuous)
Methotrexate ________ _______________
IV, (20 - 25mg)
Fluorouracil_______________ ________ ________________
IV, (500mg)
(Attach copy of dosing schedule with weekly counts)
2. Surgical intervention prior to chemotherapy
 1____lumpectomy
 2____simple mastectomy
 3____modified mastectomy
 4____radical mastectomy
 5____unknown
3. Antiemetics for home use (chart review with patient
confirmation)
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What is the highest number of doses used to control
nausea in one day? __________
During what week of treatment did this occur? _____
4. Pain medications for home use (chart review with patient 
confirmation)
What is the highest number of doses used to control 
pain in one day? __________
5.
During what week of treatment did this occur?
Comorbidity
1 anemia 2 arthritis
3 alcohol/drug abuse 4 asthma
5 bronchitis 6 cancer
7 CHF 8 COPD
9 cirrhosis of liver 10 chronic fatigue
syndrome
11 diabetes 12 emphysema
13 fibromyalgia 14 GI bleeding
15 heart disease 16 hepatitis
17 infectious disease 18 kidney disease
19 MI 20 migraines
21 psychiatric disorder
22 peripheral vascular■ 23 seizures
24
disease
stroke 25 ulcer
other
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APPENDIX H
Consent to Participate in Study
I am aware that this is a study of how people view certain 
important issues related to their health. I also understand 
that this study will examine how I feel just after I receive 
my chemotherapy treatment. I understand that the knowledge 
gained is expected to help nurses and physicians provide 
health care in a manner which will be responsive to the 
needs of patients receiving chemotherapy.
I also understand that:
1. participation in this study will involve a brief 
interview that will be conducted at my eight week 
appointment for chemotherapy. Participation will 
also include five paper and pencil questionnaires to 
be completed. The first and second forms will deal 
with my feelings about my illness and treatment.
The third questionnaire will deal with the support 
systems which are available to me. The forth 
questionnaire will deal with how I view certain 
issues related to my health. The fifth 
questionnaire will deal with general information 
about how I feel after my chemotherapy. Four 
questionnaires will be given to me for completion at 
the time of my appointment. One questionnaire will 
be given to me so that I can complete it in my home.
2. there are no anticipated physical or emotional risks 
as a result of participation in this study.
3. completion of the questionnaires may increase 
feelings such as anxiety or depression
4. the information I provide will be kept strictly 
confidential and the data will be coded so that 
identification of individual participants will not 
be possible.
5. a summary of the results will be made available to 
me upon my request.
I acknowledge that:
In giving my consent, I understand that my 
participation in this study is voluntary and that I 
may withdraw at any time without affecting the care 
I receive from my physicians or the staff.
I understand I will receive no payment for my 
participation.
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The investigator, Denise Bakker, has my permission 
to review my chart regarding my chemotherapy drugs 
and dosage.
I authorize the investigator to release the 
information obtained in this study to scientific 
literature. I understand that I will not be 
identified by name.
I have been given an opportunity to ask questions 
regarding this research study, and that these 
questions have been answered to my satisfaction.
I acknowledge that I have read and understand the above 
information and that I agree to participate in this study.
Denise Bakker 
Principle Investigator 
(616) 394-3371
Dr. Howard Stein 
Chairman, Human Subjects 
Review Committee 
Grand Valley State 
University 
(616) 395-2476
Witness (Participant Signature)
Date (Date:
I am interested in receiving a summary of the study
results.
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Consent to Participate in Study
I am aware that this is a study of how people view certain 
important issues related to their health. I also understand 
that this study will examine how I feel just after I receive 
my chemotherapy treatment. I understand that the knowledge 
gained is expected to help nurses and physicians provide 
health care in a manner which will be responsive to the 
needs of patients receiving chemotherapy.
I also understand that:
1. participation in this study will involve a brief 
interview that will be conducted on day eight of my 
second course of chemotherapy. Participation will 
also include five paper and pencil questionnaires to 
be completed. The first and second forms will deal 
with my feelings about my illness and treatment.
The third questionnaire will deal with the support 
systems which are available to me. The forth 
questionnaire will deal with how I view certain 
issues related to my health. The fifth 
questionnaire will deal with general information 
about how I feel after my chemotherapy. Four 
questionnaires will be given to me for completion at 
the time of my appointment. One questionnaire will 
be given to me so that I can complete it in my home.
2. there are no anticipated physical or emotional risks 
as a result of participation in this study.
3. completion of the questionnaires may increase 
feelings such as anxiety or depression
4. the information I provide will be kept strictly 
confidential and the data will be coded so that 
identification of individual participants will not 
be possible.
5. a summary of the results will be made available to 
me upon my request.
I acknowledge that:
In giving my consent, I understand that my 
participation in this study is voluntary and that I 
may withdraw at any time without affecting the care 
I receive from my physicians or the staff.
I understand I will receive no payment for my 
participation.
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The investigator, Denise Bakker, has my permission 
to review my chart regarding my chemotherapy drugs 
and dosage.
I authorize the investigator to release the 
information obtained in this study to scientific 
literature. I understand that I will not be 
identified by name.
I have been given an opportunity to ask questions 
regarding this research study, and that these 
questions have been answered to my satisfaction.
I acknowledge that I have read and understand the above 
information and that I agree to participate in this study.
Denise Bakker 
Principle Investigator 
(616) 394-3371
Dr. Howard Stein 
Chairman, Human Subjects 
Review Committee 
Grand Valley State 
University 
(616) 895-2476
Witness (Participant Signature]
Date (Date:
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